Condition: Non Small Cell Lung Cancer · Colorectal Cancer · Cervical Cancer · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
This description comes directly from the study's public registry record.
yongchang zhang, Ph.D. · +86 13873123436 · zhangyongchang@csu.edu.cn
Always discuss trial participation with your own doctor first.
| Hunan Provincial Tumor Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07202364